University of Buffalo Clinical and Translational Science Institute

布法罗大学临床与转化科学研究所

• 批准号: 10516562
• 负责人: Timothy F Murphy
• 金额: $ 3.42万
• 依托单位: STATE UNIVERSITY OF NEW YORK AT BUFFALO
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-08-12 至 2024-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10516562
• 关键词: Advertising; Area; Atherosclerosis; Award; Biometry; Biostatistics Core; Buffaloes; Center for Translational Science Activities; Cities; Clinic; Clinical; Clinical Research; Clinical Sciences; Clinical Trials Design; Communication; Communities; Competence; Consultations; Core Facility; Data; Databases; Development; Diverse Workforce; Educational workshop; Environment; Experimental Designs; Flow Cytometry; Foundations; Funding; Future; Gender; Good Clinical Practice; Growth; Health; Health Care Research; Health Sciences; Healthcare; Healthcare Systems; Heart; Hispanic; Individual; Influentials; Institutes; Institution; Knowledge; Laboratories; Longevity; Medical; Medical Education; Mentors; Microscope; New York; Parents; Patients; Pediatric Hospitals; Population; Process; Public Health; Public Health Informatics; Recording of previous events; Reduce health disparities; Registries; Research; Research Design; Research Institute; Research Training; Schools; Science; Series; Special Population; Speed; Strategic Planning; Testing; Training; Translational Research; Translations; Underrepresented Minority; Universities; Vision; Work; Workforce Development; biomedical informatics; community engagement; digital; education research; endothelial dysfunction; epidemiology study; ethnic diversity; experience; experimental analysis; experimental study; health disparity; improved; informatics tool; innovation; laboratory facility; medical schools; multiple data sources; next generation; novel; novel strategies; recruit; response; responsible research conduct; skills; tool; translational pipeline; volunteer

CTSA UL1 Abstract The Buffalo Translational Consortium (BTC), which includes the University at Buffalo (UB) health sciences schools, the major healthcare institutions in our region, four key research institutes and five influential community partners, have embarked on a comprehensive strategic plan to build a strong foundation for clinical and translational research in response to our community needs. Buffalo is the second most populous city in New York State and has a rich cultural history. The proportion of underrepresented minorities in Buffalo in 2018 (50%) parallels that projected for the US in 2050, making Buffalo a microcosm of what the US will look like in 30 years. A similar proportion of our population experiences health disparities. The vision for our CTSA hub is to perform innovative research across the translational spectrum to improve the health of our community and the nation. We will develop, test and share novel approaches to engage difficult-to-engage populations and reduce health disparities in our community, which represents a “population of the future”. Guided by our vision, the CTSA has catalyzed a transformation of our environment since our CTSA was first funded in August 2015 with remarkable growth in clinical and translational research. Further, in just the past year, the UB medical school has moved into a spectacular new building and our clinical partner, Kaleida Health, the largest healthcare system in the region, opened the new Oishei Children’s Hospital, both on the Buffalo Niagara Medical Campus and connected to the Clinical and Translational Research Center devoted entirely to clinical and translational research that opened in 2012. This rapid and continuing trajectory of growth in healthcare and research in the region has resulted in a new 21st century Academic Health Center with healthcare, medical education and clinical and translational research on one campus in the heart of Buffalo, creating a foundation to enhance the impact of our CTSA even further. While launching our CTSA, we have prioritized participation in the national consortium through hosting and testing Innovation Labs as a team science tool, working with multiple hubs on initiatives to solve translational research barriers and sharing tools that we have developed with the CTSA consortium, including novel health informatics tools. Our CTSA has five ambitious but achievable aims, including: 1) Accelerate innovative translational research with teams that engage communities, regional stakeholders and the national consortium; 2) Train an excellent, diverse workforce to advance translation of discoveries; 3) Enhance inclusion of special populations across the lifespan and difficult-to-engage populations; 4) Streamline clinical research processes focusing on quality and efficiency with emphasis on multisite studies; 5) Develop, test and share biomedical informatics tools to integrate data from multiple sources to speed translation. Guided by our vision to perform research to improve the health of our community and the nation, we will continue our momentum to expand translational research, train our diverse workforce, streamline processes, engage our community, and actively contribute to the national consortium. CTSA Diversity Supplement: Bacterial Derived Aortic Endothelial Dysfunction to Promote Atherosclerosis Dayron Leya Rodriquez, the candidate for this diversity supplement is of Hispanic background and completion of this supplement award will allow him to gain academic knowledge, research skills and professional development in the areas of clinical and translational research. This proposal encompasses aims of the parent CTSA UL1 award to 1) train an excellent diverse workforce to advance translational and health-related research with 2) ehnanced inclusion of special populations. To complete the proposed supplemental research, Dayron will utilize the following CTSA cores: • Biostatistics, Epidemiology and Research Design (BERD) Core: Dayron will leverage the expertise and support of his mentor Dr. Greg Wilding (Director of BERD), for appropriate statistical experimental design and analysis of all experimental data. He will also complete the BERD Statistical workshops and BERD Clinical Trials workshops series to gain competency in aspects applicable to clinical and translational research. • Workforce Development Core: Dayron will complete workshop series (each containing 4-8 individual workshops) in the areas of a) Responsible Conduct of Research, b) Scientific Communication, c) Translational Teamwork and d) Good Clinical Practice. Following completion of each series, Dayron will be awarded a Digital Badge and with completion of all these workshops will earn his CTSI Basic Micro-credential in Clinical and Translational Reseach. • Cinical Research Facilitation Core: Dayron and our research team will work with faciltators to continue successful recruitment strategies including flyers and advertising as well as access to patient databases such as the Buffalo Research Registry to recruit local volunteers. Consultation with the Community Engagement Core will facilitate appropriate community recruitment of subjects from both genders and diverse ethnic backgrounds to increase the robustness of our subject population and collected data. • Laboratory Facility Cores. Dayron will utilize the Confocal Microscope and Flow Cytometry Facility and Next Generation Seqeuncing and Expression Facility for completion of the proposed experiments.

CTSA UL1摘要 布法罗翻译联盟(BTC)，其中包括布法罗大学(UB)健康科学 学校、我区主要医疗机构、四个重点研究机构和五个有影响力的社区 合作伙伴已着手制定全面的战略计划，为临床和医疗服务奠定坚实基础 翻译研究，以回应我们的社区需求。布法罗是纽约人口第二多的城市 纽约州，拥有丰富的文化历史。2018年布法罗市代表性不足的少数族裔比例(50%) 与美国2050年的预测相似，布法罗成为美国30年后面貌的一个缩影。 我们人口中有类似比例的人经历了健康差距。我们CTSA中心的愿景是实现 跨翻译领域的创新研究，以改善我们社区和国家的健康。 我们将开发、测试和分享新的方法，让难以参与的人群参与进来，减少健康 我们社会的不平等，代表着“未来的人口”。在我们的愿景指导下，CTSA已经 自从我们的CTSA于2015年8月首次获得资金以来，我们的环境发生了显著的变化 临床和转化性研究的增长。此外，就在过去的一年里，亚利桑那州立大学医学院已经搬进了 一座壮观的新建筑和我们的临床合作伙伴，该地区最大的医疗系统Kaleida Health， 开设了新的Oishei儿童医院，既位于布法罗尼亚加拉医学院，又与 临床和翻译研究中心完全致力于临床和翻译研究，该中心于 2012年。该地区医疗保健和研究的这种快速和持续的增长轨迹导致了 新的21世纪学术健康中心，集医疗、医学教育、临床和翻译为一体 在布法罗市中心的一个校园进行研究，为提高我们CTSA的影响力奠定了基础 再远一点。在推出我们的CTSA的同时，我们通过主办优先参与国家财团 将创新实验室作为团队科学工具进行测试，与多个中心合作解决翻译 我们与CTSA联盟共同开发的研究障碍和共享工具，包括新型健康 信息学工具。我们的CTSA有五个雄心勃勃但可以实现的目标，包括：1)加快创新 与社区、区域利益攸关方和国家财团参与的团队进行翻译研究； 2)培训一支优秀的、多样化的劳动力队伍，以促进发现成果的翻译；3)加强对特殊技术的纳入 生命周期内的人群和难以参与的人群；4)简化临床研究流程 注重质量和效率，注重多点研究；5)开发、测试和共享生物医学 用于集成来自多个来源的数据以加快翻译速度的信息学工具。在我们的愿景指引下表演 为了改善我们社区和国家的健康，我们将继续扩大我们的势头 翻译研究，培训我们多样化的员工队伍，简化流程，让我们的社区参与进来，并积极 向国家财团捐款。 CTSA多样性补充：细菌来源的主动脉内皮功能障碍促进动脉粥样硬化 戴伦·莱亚·罗德里克斯(Dayron Leya Rodriquez)，这份多元化补充材料的候选人是西班牙裔背景和完成者 这项补充奖励将使他获得学术知识、研究技能和专业知识 临床和转化性研究领域的发展。这项建议包含了家长的目标 CTSA UL1奖旨在1)培训一支优秀的多元化劳动力队伍，以推动翻译和健康相关研究 2)加强对特殊人群的包容。 为了完成拟议的补充研究，戴龙将使用以下CTSA核心： ·生物统计学、流行病学和研究设计(BERD)核心：戴龙将利用专业知识 和他的导师Greg Wilding博士(BERD主任)的支持，以进行适当的统计实验设计 并对所有实验数据进行分析。他还将完成BERD统计研讨会和BERD临床 试验研讨会系列，以获得适用于临床和转化性研究方面的能力。 ·劳动力发展核心：戴龙将完成系列研讨会(每个研讨会包含4-8名个人 讲习班)a)负责任的研究行为，b)科学交流，c)翻译 团队合作和d)良好的临床实践。 在每个系列完成后，戴龙将被授予数字徽章，并在所有这些完成后 研讨会将获得他在临床和翻译研究方面的CTSI基本微观证书。 ·临床研究促进核心：戴龙和我们的研究团队将与促进者合作，继续 成功的招聘策略，包括传单和广告，以及访问患者数据库，如 作为布法罗研究登记处招募当地志愿者。与社区参与进行协商 CORE将促进适当的社区招募来自不同性别和不同种族的学科 背景以增加我们受试者群体和收集的数据的稳健性。 ·实验室设施核心。戴龙公司将利用共聚焦显微镜和流式细胞仪设备 下一代测序和表达设施，用于完成拟议的实验。